Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2006 3
2008 1
2010 1
2011 4
2012 3
2013 2
2015 1
2017 1
2018 4
2019 2
2020 3
2021 3
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

25 results
Results by year
Filters applied: . Clear all
Page 1
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ. Moss DJH, et al. Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Lancet Neurol. 2017. PMID: 28642124
BACKGROUND: Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. ...We generated a parallel progression score using data from 1773 previously genotyped participants from the European Huntington's Disease Network REGISTRY study of …
BACKGROUND: Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. ...We generated a parallel progress …
International Guidelines for the Treatment of Huntington's Disease.
Bachoud-Lévi AC, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, Craufurd D, Reilmann R, De Michele G, Rae D, Squitieri F, Seppi K, Perrine C, Scherer-Gagou C, Audrey O, Verny C, Burgunder JM. Bachoud-Lévi AC, et al. Front Neurol. 2019 Jul 3;10:710. doi: 10.3389/fneur.2019.00710. eCollection 2019. Front Neurol. 2019. PMID: 31333565 Free PMC article.
The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommendations for everyday clinical practice for treatment of Huntington's disease (HD). ...
The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommenda …
Cannabinoids for Treatment of Dystonia in Huntington's Disease.
Saft C, von Hein SM, Lücke T, Thiels C, Peball M, Djamshidian A, Heim B, Seppi K. Saft C, et al. J Huntingtons Dis. 2018;7(2):167-173. doi: 10.3233/JHD-170283. J Huntingtons Dis. 2018. PMID: 29562549
BACKGROUND: Motor symptoms in Huntington's disease (HD) are heterogeneous with dystonia being described as a symptom with a very high prevalence not only in juvenile cases. ...In addition we review the current literature concerning the use of cannabinoids in HD. METHOD: Th …
BACKGROUND: Motor symptoms in Huntington's disease (HD) are heterogeneous with dystonia being described as a symptom with a very high …
Seminar on choreas.
Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Cardoso F, et al. Lancet Neurol. 2006 Jul;5(7):589-602. doi: 10.1016/S1474-4422(06)70494-X. Lancet Neurol. 2006. PMID: 16781989 Review.
Diagnostic work-up can be straightforward in patients with a positive family history of Huntington's disease or acute-onset hemichorea in patients with lacunar stroke, but it can be a challenging and complex task in rare autoimmune or genetic choreas. Principles of managem …
Diagnostic work-up can be straightforward in patients with a positive family history of Huntington's disease or acute-onset hemichore …
An MDS Evidence-Based Review on Treatments for Huntington's Disease.
Ferreira JJ, Rodrigues FB, Duarte GS, Mestre TA, Bachoud-Levi AC, Bentivoglio AR, Burgunder JM, Cardoso F, Claassen DO, Landwehrmeyer GB, Kulisevsky J, Nirenberg MJ, Rosser A, Roth J, Seppi K, Slawek J, Furr-Stimming E, Tabrizi SJ, Walker FO, Vandenberghe W, Costa J, Sampaio C. Ferreira JJ, et al. Mov Disord. 2022 Jan;37(1):25-35. doi: 10.1002/mds.28855. Epub 2021 Nov 29. Mov Disord. 2022. PMID: 34842303 Review.
BACKGROUND: Huntington's disease (HD) is a rare neurodegenerative disorder with protean clinical manifestations. ...
BACKGROUND: Huntington's disease (HD) is a rare neurodegenerative disorder with protean clinical manifestations. ...
Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study.
McNulty P, Pilcher R, Ramesh R, Necuiniate R, Hughes A, Farewell D, Holmans P, Jones L; REGISTRY Investigators of the European Huntington's Disease Network. McNulty P, et al. J Huntingtons Dis. 2018;7(3):209-222. doi: 10.3233/JHD-170263. J Huntingtons Dis. 2018. PMID: 30103338
BACKGROUND: People with Huntington's disease (HD) have been observed to have lower rates of cancers. OBJECTIVE: To investigate the relationship between age of onset of HD, CAG repeat length, and cancer diagnosis. METHODS: Data were obtained from the European Huntington
BACKGROUND: People with Huntington's disease (HD) have been observed to have lower rates of cancers. OBJECTIVE: To investigate the re …
Time will tell: Decision making in premanifest and manifest Huntington's disease.
Heim B, Peball M, Saft C, von Hein SM, Ellmerer P, Piater JM, Seppi K, Djamshidian A. Heim B, et al. Brain Behav. 2020 Nov;10(11):e01843. doi: 10.1002/brb3.1843. Epub 2020 Sep 26. Brain Behav. 2020. PMID: 32978893 Free PMC article.
OBJECTIVE: To investigate cognitive flexibility in premanifest and manifest Huntington's disease (HD). BACKGROUND: HD is an autosomal dominant neurodegenerative disease characterized by motor, cognitive, and behavioral abnormalities with typical motor symptoms. ...
OBJECTIVE: To investigate cognitive flexibility in premanifest and manifest Huntington's disease (HD). BACKGROUND: HD is an autosomal …
Suicidal ideation in a European Huntington's disease population.
Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; REGISTRY investigators of the European Huntington's Disease Network. Hubers AA, et al. J Affect Disord. 2013 Oct;151(1):248-58. doi: 10.1016/j.jad.2013.06.001. Epub 2013 Jul 20. J Affect Disord. 2013. PMID: 23876196 Free article.
BACKGROUND: Previous studies indicate increased prevalences of suicidal ideation, suicide attempts, and completed suicide in Huntington's disease (HD) compared with the general population. This study investigates correlates and predictors of suicidal ideation in HD. METHOD …
BACKGROUND: Previous studies indicate increased prevalences of suicidal ideation, suicide attempts, and completed suicide in Huntington
Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.
Cubo E, González M, del Puerto I, de Yébenes JG, Arconada OF, Gabriel y Galán JM; European Huntington's Disease Initiative Study Group. Cubo E, et al. Mov Disord. 2012 Mar;27(3):439-42. doi: 10.1002/mds.24062. Epub 2011 Dec 9. Mov Disord. 2012. PMID: 22162184
BACKGROUND: Classically, clinical trials are based on the placebo-control design. Our aim was to analyze the placebo effect in Huntington's disease. METHODS: Placebo data were obtained from an international, longitudinal, placebo-controlled trial for Huntington's di …
BACKGROUND: Classically, clinical trials are based on the placebo-control design. Our aim was to analyze the placebo effect in Huntington
25 results